Induced pluripotent stem (iPS) cells are a type of artificial pluripotent stem cell induced by the epigenetic silencing of somatic cells by the Yamanaka factors. Advances in iPS cell reprogramming technology will allow aging or damaged cells to be replaced by a patient’s own rejuvenated cells. However, tissue that is senescent or pathologic has a relatively low reprogramming efficiency as compared with juvenile or robust tissue, resulting in incomplete reprogramming; iPS cells generated from such tissue types do not have sufficient differentiation ability and are therefore difficult to apply clinically. Here, we develop a new reprogramming method and examine it using myofibroblasts, which are pathologic somatic cells, from patient skin tissue and from each of the four heart chambers of a recipient heart in heart transplant surgery. By adjusting the type and amount of vectors containing transcriptional factors for iPS cell reprogramming, as well as adjusting the transfection load and culture medium, the efficiency of iPS cell induction from aged patient skin-derived fibroblasts was increased, and we successfully induced iPS cells from myocardial fibroblasts isolated from the pathologic heart of a heart transplant recipient.
Background: The prognosis of acute decompensated heart failure (ADHF) and heart failure (HF) with atrial fibrillation (AF) has been dismal. This study was performed to investigate the clinical outcomes of catheter ablation (CA) performed in patients with concurrent ADHF and AF. Methods: We retrospectively analyzed ADHF patients with AF who were admitted to our institution from 2007 to 2017. Results: In total, 472 patients were included in this study, with a mean follow-up duration of 32.8 ± 32.9 months. The 5-year event-free rate (cardiovascular death and HF hospitalization) was 61.4%, and the 10-year event-free rate was 42.7%. A comparative analysis of the event group and control group revealed that patients in the event group were older (event group vs. control group: 72.1 ± 11.0 vs. 68.8 ± 13.4 years, p = 0.008) and had a higher proportion of Clinical Scenario 3 classifications (event group vs. control group: 24% vs. 12%, p = 0.001). Notably, patients in the event group had a lower sinus rhythm maintenance rate (event group vs. control group: 17% vs. 31%, p < 0.001) and CA rate (event group vs. control group: 9% vs. 21%, p = 0.003). The CA group had a higher event-free rate than the non-CA group, and this trend persisted even after matching the patients’ backgrounds (log-rank test: p < 0.001). Conclusions: Patients presenting with AF at the onset of ADHF showed a poor prognosis, whereas CA demonstrated potential for improving the prognosis for some of these patients.
Background: Wearable cardioverter-defibrillators (WCDs) are equipped with the TRENDS remote-monitoring system, enabling continuous assessment of arrhythmias, physiological parameters, and patient-reported outcomes. This study evaluated the clinical utility of TRENDS-integrated WCD management and compared it with a historical control. Methods: We prospectively analyzed 36 consecutive patients who received a WCD with TRENDS between 2019 and 2024 and compared them with 30 historical controls treated before the implementation of TRENDS. Results: The WCD indications were heart failure as primary prevention (64%) and acute coronary syndrome with ventricular arrhythmias (28%). Among 18 patients who met the criteria for an implantable cardioverter-defibrillator (ICD), including 1 patient with WCD shock, 9 ultimately underwent ICD implantation. The mean daily WCD wear-time was 21.3 h and did not differ significantly from that of the historical control. The response rate to health-related questionnaires was 89%. TRENDS detected symptom exacerbation in 31% of patients, weight gain in 19% of patients, and missed medication in 19% of patients. Daily step-count was significantly lower in patients with ICD indications than in those without (5012 ± 2980 steps vs. 7977 ± 3584 steps, p = 0.01). TRENDS data also aided in initiating anticoagulation therapy and optimizing beta-blocker therapy. Conclusions: TRENDS provided clinically actionable physiologic and patient-reported information that supported individualized cardiovascular management.
Induced pluripotent stem cell (iPSC) technology has transformed regenerative medicine by enabling the generation of patient-specific pluripotent cells without the ethical constraints associated with embryonic stem (ES) cells. Over the past two decades, advances in nonintegrating reprogramming methods, optimization of mesenchymal-to-epithelial transition (MET), and refinement of culture conditions have markedly improved the safety and efficiency of iPSC generation. iPSC-derived cardiomyocytes (iPSC-CMs) have emerged as a particularly promising application, given the extremely limited regenerative capacity of adult human myocardium. Stepwise modulation of developmental signaling pathways – including Activin/Nodal, bone morphogenetic protein (BMP), and the biphasic Wnt/β-catenin axis – has enabled highly efficient cardiac differentiation, while metabolic selection strategies have facilitated the purification of cardiomyocytes to near-homogeneous populations. Despite these advances, iPSC-CMs remain structurally and metabolically immature, lacking key features of adult myocardium such as T-tubules, fatty-acid-dependent metabolism, and polyploidization. Recent progress in three-dimensional (3D) tissue engineering, microfluidic organ-on-chip systems, electrical pacing, and metabolic conditioning has begun to address these limitations, bringing iPSC-derived tissues closer to adult physiological states. Clinically, Japan’s approval of the first iPSC-derived therapeutic products in 2026 – including cardiomyocyte sheets and intramyocardial spheroid injection – marks a pivotal transition from experimental therapy to real-world medical application. Looking forward, the development of immune-evasive “universal cardiomyocytes” and industrial-scale manufacturing pipelines promises to expand the accessibility and therapeutic potential of iPSC-based cardiac regeneration.